159 related articles for article (PubMed ID: 30261468)
1. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Sorrenti V; Pittalà V; Romeo G; Amata E; Dichiara M; Marrazzo A; Turnaturi R; Prezzavento O; Barbagallo I; Vanella L; Rescifina A; Floresta G; Tibullo D; Di Raimondo F; Intagliata S; Salerno L
Eur J Med Chem; 2018 Oct; 158():937-950. PubMed ID: 30261468
[TBL] [Abstract][Full Text] [Related]
2. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
[TBL] [Abstract][Full Text] [Related]
3. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
4. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
[TBL] [Abstract][Full Text] [Related]
5. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
6. Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.
Salerno L; Romeo G; Modica MN; Amata E; Sorrenti V; Barbagallo I; Pittalà V
Eur J Med Chem; 2017 Dec; 142():163-178. PubMed ID: 28756878
[TBL] [Abstract][Full Text] [Related]
7. Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
Wei D; Lu T; Ma D; Yu K; Li X; Chen B; Xiong J; Zhang T; Wang J
J Cell Physiol; 2019 Apr; 234(4):5252-5263. PubMed ID: 30256411
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
[TBL] [Abstract][Full Text] [Related]
10. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
11. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
12. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
13. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
17. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia.
Ciaffaglione V; Consoli V; Intagliata S; Marrazzo A; Romeo G; Pittalà V; Greish K; Vanella L; Floresta G; Rescifina A; Salerno L; Sorrenti V
Molecules; 2022 May; 27(10):. PubMed ID: 35630697
[TBL] [Abstract][Full Text] [Related]
18. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
19. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
20. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
Tibullo D; Barbagallo I; Giallongo C; La Cava P; Parrinello N; Vanella L; Stagno F; Palumbo GA; Li Volti G; Di Raimondo F
Curr Pharm Des; 2013; 19(15):2765-70. PubMed ID: 23092325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
